Use of Hydralazine and Valproic Acid in Advanced Solid Tumor Malignancies

Inclusion Criteria:

All patients with lung cancer who have disease which has been previously treated and/or for which there is no acceptable standard treatment regimen available, and cannot be treated definitively with either surgery or radiotherapy.
All will be appropriate candidates for treatment, and are not candidates for treatment with protocols of higher priority.
All patients should have an ECOG/Zubrod/SWOG performance status of less than 2 at the time of the initiation of therapy
Adequate end-organ function
No severe comorbid disease
Ability to provide informed consent.
Signed Informed Consent
ECOG/Zubrod/SWOG Performance Status less than 2
Life expectancy greater than 8 weeks
Male or female' age greater than 18 years
Patients of childbearing potential must be using an effective means of contraception.
Histologic diagnosis of lung cancer that is advanced and cannot be treated adequately by radiotherapy or surgery; or metastatic disease, and for which there is no standard chemotherapeutic option remaining or available
All participants must have either previously received or refused standard chemotherapy
Baseline laboratory values (bone marrow, renal, hepatic):

Adequate bone marrow function:

Absolute neutrophil count greater than 1000/µL
Platelet count greater than 100'000/µL

Renal function:

a. Serum creatinine less than 2.0 mg %

Hepatic function:

Bilirubin less than 1.5x normal
Serum calcium less than 12 mg/dl

Exclusion Criteria

Pregnant or lactating females
Myocardial infarction or ischemia within the 6 months before Cycle 0' Day 0
Uncontrolled' clinically significant dysrhythmia
Prior radiotherapy to an indicator lesion unless there is objective evidence of tumor growth in that lesion
Prior autoimmune disease
Uncontrolled metastatic disease of the central nervous system
Radiotherapy within the 2 weeks before Cycle 1' Day -14
Surgery within the 2 weeks before Cycle 1' Day -14
Any co morbid condition that' in the view of the attending physician' renders the patient at high risk from treatment complications